SCHEMBL29580149

SCHEMBL29580149

C[C@H](N)C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.84

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
IARS1 P41252 4/20 0.84
SARS1 P49591 3/20 0.84
MARS1 P56192 2/20 0.79
CA1 P00915 1/20 0.72
CA2 P00918 1/20 0.72
CA4 P22748 1/20 0.72
CA9 Q16790 1/20 0.72
TARS1 P26639 2/20 0.68
LARS1 Q9P2J5 2/20 0.68
ADORA3 P0DMS8 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13773429 1.00 IARS1 (0.84) IARS1SARS1MARS1CA1CA2
Alasa SCHEMBL21067643 0.87 TARS1 (0.87) IARS1SARS1MARS1TARS1LARS1
Alasa SCHEMBL4320823 0.87 TARS1 (0.87) IARS1SARS1MARS1TARS1LARS1
Alasa SCHEMBL29531843 0.87 TARS1 (0.87) IARS1SARS1MARS1TARS1LARS1
SCHEMBL29737838 0.84 CA1 (1.00) IARS1SARS1MARS1CA1CA2
SCHEMBL2489469 0.84 CA1 (1.00) IARS1SARS1MARS1CA1CA2
SCHEMBL2489474 0.84 CA1 (1.00) IARS1SARS1MARS1CA1CA2
SCHEMBL14201599 0.84 CA1 (1.00) IARS1SARS1MARS1CA1CA2
SCHEMBL21067691 0.81 TARS1 (1.00) IARS1SARS1MARS1TARS1LARS1
SCHEMBL4316150 0.81 TARS1 (1.00) IARS1SARS1MARS1TARS1LARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118056906-A Method for removing target nucleic acid fragments from nucleic acid constructs 上海复诺健生物科技有限公司 2024-05-21 CN disclosed
CN-115942978-A Antibody-drug conjugates comprising anti-B7-H3 antibodies 尹图赛利有限公司 2023-04-07 CN disclosed
CN-109276717-B Linked gene inactivation biomarkers and targets for cancer therapy 得克萨斯系统大学董事会 2022-04-12 CN disclosed